Biology and lung function tests
| Subjects | 1465 |
| α1-antitrypsin test | 157 (10.8) |
| <0.8 g·L−1 | 6 (3.8) |
| 0.8–0.99 g·L−1 | 4 (2.6) |
| ≥1 g·L−1 | 145 (93.5) |
| Mean result g·L−1 | 1.3±0.4 |
| Pulmonary function tests | 1321 (98.2) |
| Time since last spirometry months | 2.1±8 |
| Last spirometry assessed during the visit | 862 (65.6) |
| ≤6 months | 329 (25) |
| 6–12 months | 64 (4.9) |
| >12 months | 59 (4.5) |
| Missing data | 7 |
| Pre-bronchodilator FEV1 % pred | 72.1±20.6 |
| Post-bronchodilator FEV1 % pred | 77.1±20.5 |
| Pre-bronchodilator FEV1/FVC % pred | 70.2±14.4 |
| FEV1/FVC <70% pred | 20% |
| FEV1 evolution after β2-agonists % | |
| No evolution | 243 (18.5) |
| Increase <10% | 363 (27.1) |
| Increase ≥10% | 304 (33.4) |
| Missing data | 411 |
| Exhaled nitric oxide measurements | 64 (4.4) |
| Results ppb | 37.5±26.2 |
| Chest CT scan | 754 (51.8) |
| Bronchiectasis | 156 (22) |
| Bronchial wall thickening | 307 (44) |
| Emphysema | 108 (15,5) |
| ENT CT scan | 466 (16) |
| Absence of clinical signs | 135 (30.7) |
| Polyps | 119 (27) |
| Chronic sinusitis | 186 (42.3) |
| Missing data | 26 |
Data are presented as n, n (%) or mean±sd. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; CT: computed tomography; ENT: ear, nose and throat.